![]() | Omar Hasan Ali |
Prominent publications by Omar Hasan Ali
Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor infiltrating lymphocytes were characterized for CD3, CD4, and CD8 expressions by immunohistochemistry. 4/9 ...
Known for Lymph Node | Tumor Infiltrating | Melanoma Patients | Response Ipilimumab | Checkpoint Inhibitors |
BACKGROUND: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1) therapy frequently entails immune-related adverse events (irAEs), and biomarkers to predict irAEs are lacking. Although checkpoint inhibitors have been found to reinvigorate T cells, the relevance of autoantibodies remains elusive.
OBJECTIVE: Our aim was to explore whether IgG autoantibodies directed against coexpressed antigens by tumor tissue and healthy skin correlate with skin irAEs and therapy ...
Known for Checkpoint Inhibitors | Cell Lung | Skin Iraes | Death 1 | Patients Baseline |
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
[ PUBLICATION ]
BackgroundLong-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed.MethodsWe investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. ...
Known for Melanoma Patients | Antibodies Monoclonal | Response Survival | Reliable Biomarkers | Immune Checkpoint Inhibitors |
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
[ PUBLICATION ]
Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) in 40 patients with ...
Known for Skin Reactions | Patients Nsclc | Cell Lung | Tumor Responses | Immune Checkpoint Inhibitors |
Short‐ and long‐term effects of two emollients on itching and skin restoration in xerotic eczema
[ PUBLICATION ]
Pruritus is associated with various skin diseases, dry skin, and with it an impaired skin barrier function. The study objective was to investigate short-term and long-term effects of two emollients on symptoms and skin barrier functions in xerotic eczema. Randomized, double-blind, study enrolling females/males, with bilateral itching. Two emollients, containing lactic acid and refined almond oil with/without polidocanol were administered on left versus right body sides. Itching severity, ...
Known for Itching Severity | Dry Skin | Publication Administration | Eczema Emollients | Barrier Function |
Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
[ PUBLICATION ]
PURPOSE: Characterize ocular adverse events (oAEs) caused by immune checkpoint inhibitors (ICIs).
METHODS: Retrospective analysis of 41,674 cancer patients in the FDA Adverse Event Reporting System (FAERS) pharmacovigilance database receiving anti-PD-1/PD-L1, anti-CTLA-4, or anti-PD-1+ anti-CTLA-4 combination. Reporting odds ratio (ROR) was used to approximate oAE rate across regimens and indications.
RESULTS: The most common indications were lung cancer (27.3%) and melanoma (22.7%); ...
Known for Immune Checkpoint Inhibitors | Lung Cancer | Adverse Event | Pd1 L1 | Methods Retrospective |
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
[ PUBLICATION ]
Background: Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking.
Patients and methods: We prospectively collected clinical and laboratory data of 56 non-small cell lung cancer patients treated with a checkpoint inhibitor. The aim was to identify baseline parameters correlating with worse outcome and to create a risk score that ...
Known for Checkpoint Inhibitors |
Omar Hasan Ali: Influence Statistics
Concept | World rank |
---|---|
iraes 04 | #9 |
patients iciinduced hepatitis | #10 |
occurrence iciinduced hepatitis | #10 |
iciinduced hepatitis iraes | #10 |
occurrence ici | #10 |
iraes iciinduced hepatitis | #10 |
occurrence prospective cohort | #11 |
collagens programmed | #13 |
skin coexpress bp180 | #13 |
skinspecific igg | #13 |
patients hepatitis cohort | #14 |
immunological autoantigens | #15 |
iciinduced hepatitis | #15 |
iraes organs | #15 |
nsclc skin | #16 |
bp180specific igg | #16 |
diseases nsclc | #18 |
baseline therapy response | #19 |
results40 patients | #19 |
organs iraes | #20 |
putatively factors | #23 |
associations ici | #25 |
alleles ici | #25 |
iraes skin | #27 |
coexpressed antigens | #28 |
survival checkpoint inhibitors | #29 |
igg nsclc | #30 |
ici hepatitis | #31 |
kantonsspital gallen | #35 |
04 therapy | #35 |
skin iraes | #42 |
iraes checkpoint inhibitors | #42 |
itching severity | #49 |
iraes therapy | #51 |
nsclc patients baseline | #51 |
skin adverse events | #58 |
pruritus survival | #62 |
iraes biomarkers | #82 |
bp180 specific | #86 |
40 recruited | #89 |
Key People For Checkpoint Inhibitors
Omar Hasan Ali:Expert Impact
Concepts for whichOmar Hasan Alihas direct influence:Checkpoint inhibitors, Skin reactions, Therapy response, Cell lung, Melanoma patients, Iciinduced hepatitis, Small cell, Immune checkpoint inhibitors.
Omar Hasan Ali:KOL impact
Concepts related to the work of other authors for whichfor which Omar Hasan Ali has influence:Immune checkpoint inhibitors, Cell lung, Patients iraes, Sensitive skin, Clinical benefit, Metastatic melanoma, Checkpoint blockade.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |